Houston, USA-based Fabre-Kramer Pharmaceuticals and UK drug major GlaxoSmithKline have been issued with a "not approvable" letter by the Food and Drug Administration regarding the co-developed major depressive disorder drug, gepirone ER. The decision, which follows the submission of additional supporting data earlier this year (Marketletter May 14), is a setback for both companies, but particularly for GSK which had hoped that, following a series of high profile problems, gepirone would bolster its product range and match analysts' peak sales forecasts of between $800.0 million and $1.6 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze